NeoGenomics Inc, Ft. Myers, Fla, has validated and introduced a lab-developed fluorescent in situ hybridization (FISH) assay for the surveillance of patients with Barrett's Esophagus (BE).
The test is highly sensitive for the detection of the presence of esophageal cancer or high-grade dysplasia indicative of precancerous changes.
NeoGenomics' NeoSITE BE FISH test was designed specifically to be performed on brushing samples and can be used as an objective and easier means to aid in routine surveillance of BE patients.
Trials showed initial sensitivity of 86% and specificity of 67% when the NeoGenomic's proprietary algorithms were used to assist with interpreting the FISH results. Reported sensitivity and specificity levels were even higher when brushing samples were obtained from nodules rather than pan-brushing.
[Source: NeoGenomics]
 |
 |
 |
 |
CLP is the only magazine that focuses exclusively on products and technology for the clinical lab industry. Every month, CLP's editorial provides 45,000 pathologists, lab managers, administrators and technologists with comprehensive coverage of new products and technology.
RSS